Cargando…

Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review

Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hryhorowicz, Szymon, Kaczmarek-Ryś, Marta, Zielińska, Aleksandra, Scott, Rodney J., Słomski, Ryszard, Pławski, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727741/
https://www.ncbi.nlm.nih.gov/pubmed/35003109
http://dx.doi.org/10.3389/fimmu.2021.790803
_version_ 1784626585806045184
author Hryhorowicz, Szymon
Kaczmarek-Ryś, Marta
Zielińska, Aleksandra
Scott, Rodney J.
Słomski, Ryszard
Pławski, Andrzej
author_facet Hryhorowicz, Szymon
Kaczmarek-Ryś, Marta
Zielińska, Aleksandra
Scott, Rodney J.
Słomski, Ryszard
Pławski, Andrzej
author_sort Hryhorowicz, Szymon
collection PubMed
description Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in modulating many physiological processes including intestinal homeostasis, modulation of gastrointestinal motility, visceral sensation, or immunomodulation of inflammation in IBD. It consists of cannabinoid receptors (CB1 and CB2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (Anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ECS in inflammatory bowel disease. This review summarizes the role of ECS components on intestinal inflammation, suggesting the advantages of cannabinoid-based therapies in inflammatory bowel disease.
format Online
Article
Text
id pubmed-8727741
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87277412022-01-06 Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review Hryhorowicz, Szymon Kaczmarek-Ryś, Marta Zielińska, Aleksandra Scott, Rodney J. Słomski, Ryszard Pławski, Andrzej Front Immunol Immunology Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in modulating many physiological processes including intestinal homeostasis, modulation of gastrointestinal motility, visceral sensation, or immunomodulation of inflammation in IBD. It consists of cannabinoid receptors (CB1 and CB2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (Anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ECS in inflammatory bowel disease. This review summarizes the role of ECS components on intestinal inflammation, suggesting the advantages of cannabinoid-based therapies in inflammatory bowel disease. Frontiers Media S.A. 2021-12-22 /pmc/articles/PMC8727741/ /pubmed/35003109 http://dx.doi.org/10.3389/fimmu.2021.790803 Text en Copyright © 2021 Hryhorowicz, Kaczmarek-Ryś, Zielińska, Scott, Słomski and Pławski https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hryhorowicz, Szymon
Kaczmarek-Ryś, Marta
Zielińska, Aleksandra
Scott, Rodney J.
Słomski, Ryszard
Pławski, Andrzej
Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
title Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
title_full Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
title_fullStr Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
title_full_unstemmed Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
title_short Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
title_sort endocannabinoid system as a promising therapeutic target in inflammatory bowel disease – a systematic review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727741/
https://www.ncbi.nlm.nih.gov/pubmed/35003109
http://dx.doi.org/10.3389/fimmu.2021.790803
work_keys_str_mv AT hryhorowiczszymon endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview
AT kaczmarekrysmarta endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview
AT zielinskaaleksandra endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview
AT scottrodneyj endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview
AT słomskiryszard endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview
AT pławskiandrzej endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview